A high-quality preclinical AAV packaging platform supported by a team with extensive experience in producing various AAV serotypes and custom AAV capsids.
uBriGene’s skilled technical team delivers high-quality research-grade and preclinical AAV vectors for a variety of AAV serotypes. Our analytical teams can develop AAV-specific analytical methods, including AAV genome titer and full/empty ratio assessments.
Services | Description | Estimated Timeline | Pricing |
---|---|---|---|
Regular Scale AAV Packaging | 1E13 vg/mL, 2x250uL, AAV production service for high yield AAV serotypes, IDX gradient purification (5E12 vg/mL for AAV2, AAV6* low yield serotypes) | ||
Large Scale AAV Packaging | 1E13 vg/mL, 1 mL, AAV production service for high yield AAV serotypes, IDX gradient purification (5E12 vg/mL for AAV2, AAV6* low yield serotypes). | 2-3 Weeks | Request a Quote |
Preclinical AAV Packaging | >2E13 vg total AAV virus production. IDX gradient or chromatographic purification. | ||
GMP AAV Manufacturing | cGMP AAV manufacturing | Varies | View Details |
*Concentrated AAV2 and AAV6 can also be provided at additional cost.
Sit faucibus praesent in id natoque porta amet amet. Feugiat ullamcorper habitasse aliquet ante pharetra vitae eu morbi amet. Nunc eu leo lorem dignissim aliquet.
Streamlined AAV packaging processes
Ultracentrifugation or chromatographic purification
At uBrigene, our preclinical AAV packaging is based on the transient transfection method. AAV viral vectors are generated by transfecting HEK293 cells with AAV packaging plasmids and the gene of interest. We have developed a highly productive, scalable, and animal component-free AAV suspension production cell line.
The AAV vector upstream process is optimized for high titer production, while the downstream process includes a purification scheme that maximizes the yield of genome-containing particles. For AAV downstream purification, iodixanol (IDX) gradient ultracentrifugation is used for regular-scale AAV packaging. For preclinical-scale and GMP AAV production, chromatographic methods are employed to achieve higher purity and quality.
The advantages of membrane matrix in downstream chromatography for plasmid purification include requiring only 30% of the time compared to conventional resin. Therefore, plasmid DNA is manufactured faster and at a much lower cost.
The lysates are clarified through scalable, fully closed depth filtration, followed by a cost-effective two-step purification process using anion exchange (AEX) and hydrophobic interaction chromatography (HIC). For larger-scale production membrane matrix chromatography allows for higher flow rates.
Rhoncus duis elementum suspendisse odio amet arcu tellus. Sapien felis vestibulum euismod eget orci scelerisque id. Non ut sagittis leo et. Et pretium nisl ultrices dapibus sit euismod volutpat elementum.
uBriGene offers a full suite of in-house and custom AAV-specific assays to support vector process development and manufacturing, including QC release and stability-indicating test methods. Preclinical testing packages can be customized to meet client-specific specifications at this phase of development, including AAV genome titer, full/empty capsid ratio, purity, total virus titer, infectious titer, and more. Please view the details on the viral vector QC testing.
The advantages of membrane matrix in downstream chromatography for plasmid purification include requiring only 30% of the time compared to conventional resin. Therefore, plasmid DNA is manufactured faster and at a much lower cost.
uBriGene provides AAV packaging services using both adherent HEK293 cells and our proprietary 293XS suspension cell production systems. The advantages of the suspension cell production system include being serum-free and easily scalable for preclinical and GMP AAV production.
The AAV packaging productivity of our suspension cells, 293HS, was tested across various AAV serotypes using transient transfection methods. AAV particles were purified using chromatography.
Request a quoteA variety of naturally occurring AAV serotypes exist, each with slight variations in their capsids. The specific tissue tropism of these serotypes enables AAV to target tissues for gene therapies.
Tissue | Serotype |
---|---|
Heart | AAV9, AAV6, AAV1 |
Nerves | PHP.EB, AAV9, AAV-retro, AAV1, AAV4, AAV8, AAV5 |
Liver | AAV9, AAV8, AAV7, AAV2, AAV3 |
Lung | AAV5, AAV9, AAV6, AAV1, AAV2 |
Muscle | AAV9, AAV8, AAV7, AAV2, AAV6, myoAAV 1A |
Kidney | AAV9, AAV2, AAV5, AAV1 |
Adipose | AAVRec2, AAV1 |
Intestine | AAV8, AAV2, AAV5, AAV1 |
Pancreas | AAV9, AAV8 |
Eyes | AAV2, AAV1, AAV5 |
*Outsourced testing
Adeno-associated virus (AAV) is a small, non-enveloped virus belonging to the parvovirus family. AAV contains a 4.8 kb single-stranded DNA genome and is commonly used as a vector for delivering genetic material into cells. Due to its ability to infect both dividing and non-dividing cells and its relatively low immunogenicity, AAV is widely utilized in gene therapy applications.
Recombinant AAV (rAAV) is engineered to carry therapeutic genes flanked by inverted terminal repeats (ITRs), delivering the desired genetic material into target cells to correct or modify gene function.
uBriGene has pHelper and Rep/Cap plasmids for most AAV serotypes. For custom AAV capsids, you will need to send them to us.
Yes, we can help construct the gene of interest (GOI) into an AAV transfer vector backbone. Provide us with a gene sequence or a source of the DNA insert, and we will clone it into our AAV vector backbone or your AAV transfer vector.
Given that the AAV genome is approximately 4.8 kb, the maximum gene size that can be accommodated is around 4.6 kb. Longer gene sequences negatively affect the AAV titer during production.
No. uBriGene provides plasmid preparation services if needed.
Yes. Provide your custom Rep/Cap plasmid, and we can package the custom AAV. Yield will not be guaranteed. If needed, we can provide process development for your custom AAV capsid.
For cell culture use, AAV viruses typically require genome titration. For animal studies, we can also support additional testing, including endotoxin (LYL), purity (SDS-silver staining or CE), full/empty ratio by AUC, and potency assays. Please view full details on our AAV QC testing service.
We provide a full suite of AAV in-process testing and GMP release assays. Please view more details on GMP AAV manufacturing.
We will need 10-100ug plasmids to start the molecular cloning work.
We offer different 293 cell lines for you to choose from. We have the HEK293T adherent cell AAV production system and our high-productivity 293XS suspension cell production system. The AAV suspension cell production platform is serum-free and more scalable.
Discover the difference our AAV packaging services can make in your research. Get high-quality, high-yield AAV vectors with our state-of-the-art facilities and support.
Sit aliquam elit vitae bibendum lectus blandit dictum. Nisi porta elementum sed diam eleifend pellentesque. Quis aenean quam.
Request a QuoteAsk the plasmid DNA expert! With over 300 GMP batches in our track record and our cost-effective platform technology, we can help accelerate your clinical programs.